Everest Organics’ Aroor plant was inspected by the United States Food and Drug Administration (USFDA) from February 27, 2017 to March 3, 2017 and the regulator has made one observation. The company believes that this is of minor nature and corrective & preventive action for this observation will be presented to the regulator shortly.
Everest Organics is engaged in the business of bulk drugs and active pharmaceutical ingredients (APIs). It is involved in manufacturing of bulk drugs, such as Omeprazole, Ciprofloxacin, Dichloroflurobenzene, Naproxen and Benzimadizole.
